Introduction to Suboxone What Family Physicians Can Offer Friday April 15th, 2016 John L Bender, MD, MBA,FAAFP.

Slides:



Advertisements
Similar presentations
Cindy Powers Magrini, PharmD, BCPS
Advertisements

Contracting With HMOs:. Historic Trends in Health Care Services In 1983, DRGs were developed & the expectation was shorter inpatient stays. Schizophrenic.
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
MAPS Michigan Automated Prescription System. Exempt From Reporting Medications administered directly to patients. Dispensing of up to a 48 hour supply.
Role of the Pharmacist in Collaborative Care for Mental Health and Addiction Treatment in Medically Underserved Appalachia Sarah T. Melton, PharmD,BCPP,CGP.
DBHDS Vision: A life of possibilities for all Virginians Treatment for Opioid Addiction Public Community Treatment in Virginia Virginia Heroin and Prescription.
Swinomish Wellness Program
Sublingual Buprenorphine and Pain
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Treating opioid addiction in hospitalized medical patients Miriam Komaromy, MD, FACP Associate Director, ECHO Institute.
Recovery Centers of King County Buprenorphine Treatment Program AAP Providers Conference, April 19, 2013, Lynnwood, WA Patricia C. Knox, Ph.D.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, MA Deputy Director 1.
For Pain or Not for Pain: Methadone Madness
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Department of Health and Vanderbilt University Chronic Pain Guidelines Symposium Elizabeth Lund, Executive Director, Board of Nursing Linda Johnson, APN.
San Francisco County OBOT Pilot: Pharmacy Aspects Sharon Kotabe, PharmD Associate Administrator for Pharmaceutical Services Associate Clinical Professor.
Study Finds Persons Who Fill Buprenorphine Prescriptions Have Higher Rates of Medical Conditions Associated with Pain and Comorbid Psychiatric Disorders.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
Ph: Disclaimer: Information on this page is not a substitute for medical consultation.
Pain Management- Hydrocodone Lara Offenburger PA-C No Disclosures ©AAHCM.
Learning Disability Health Checks Health Action Plan Meeting 30 th Jan 2009.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Objectives When administering buprenorphine/naloxone in a MAP program, what are the Differences from administering other medications? Similarities.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
Medicated Assisted Treatment (MAT) Terry R. Jones Director of Behavioral Health.
Medstat MercuryMD Micromedex PDR Solucient Substance abuse medications: Trends and prescribing patterns by physician specialty November 5, 2007 American.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
SOONERCARE PAIN MANAGEMENT PROGRAM. SOONERCARE PAIN MANAGEMENT PROGRAM The SoonerCare Pain Management Program is designed to equip SoonerCare providers.
The Prescription Opioid & Heroin Crisis: Addiction & Medication Assisted Treatment Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation.
Sarah Thompson, PharmD, CDOE Director of Clinical Services, Coastal Medical.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Fee for Service Revisions SFY17-18 Overview for Providers April 2016.
A System to Manage Long Term Opioid Prescribing in the Primary Care Setting Joy Nassar, MD University Medicine Foundation November 16, 2015.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Pennsylvania's Prescription Drug Monitoring Program (PDMP) May 17, 2016.
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Medical Assisted Treatment
Medication Assisted Treatment
Medication Assisted Treatment
Center of Excellence Kate Henry LCSW, CCDPD Stacey Burroughs, LPC, CAADC Behavioral Health Service Line May 15th 2017.
Reimbursement for New Medications in OTPs in New York State
Research Questions Does integration of behavioral health and primary care services, compared to simple co-location, improve patient-centered outcomes in.
Medication-Assisted Therapy at Coleman Profession Services
Caldwell County Narcotic Initiative
Place name sticker or stamp with card
San Francisco County OBOT Pilot: Pharmacy Aspects
Opioids – A Pharmaceutical Perspective on Prescription Drugs
OPIOID SAFETY. Indiana Statistics In Summary… About 100 Hoosiers die from drug overdoses every month, many from opioids such as heroin and prescription.
Telepractice Delivery of Services in OASAS Programs.
MEDICATION ASSISTED TREATMENT for OPIATE ADDICTION
Health Home Program Services for Patient 1st Medicaid Recipients
A State Targeted Response to the Opioid Crisis:
Barbara Allison-Bryan, MD
DATA 2000 Waivers The Drug Addiction Treatment Act of 2000 (DATA 2000) permits physicians who meet certain qualifications to treat opioid dependency with.
Opiate Roundtable March 29, 2018 Karen Burgess, MD
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Ten Pearls for Medication Assisted Treatment of Opiate Use Disorders
Concurrent Care For Children Who Are Enrolled In Hospice
Employees Retirement System of Texas (ERS) Changing the Script
Federal Legislative Update
Call today to speak with our caring staff.
Medication Assisted Treatment of Opioid Use Disorder
The Silent Killer in America
Presentation transcript:

Introduction to Suboxone What Family Physicians Can Offer Friday April 15th, 2016 John L Bender, MD, MBA,FAAFP

The Future is Different  If I had asked the people what they wanted, they would have asked for Faster Horses ” - Henry Ford, inventor of the Model T and the assembly line.

 Do you have an XDEA license? 1. Yes 2. No Some Polling…..

 Do you treat opiate addicts in your practice? 1. Yes 2. No Some Polling Continued…..

 Which is more difficult to manage? a. Chronic Pain Patient b. Heroin Addict c. No difference Some Polling Continued…..

 Do you have collocated/integrated behavioral health in your practice setting? 1. Yes 2. No Some Polling Continued…..

 Identify the role of the Family Physician in the care of the opiate dependent patient  Identify the role of buprenorphine and naloxone in the care of the opiate dependent patient.  Review the Federal law and DEA oversite that applies to obtaining and maintaining XDEA licensure. Learning Objectives

 Review the comorbidities that must be addressed when providing buprenorphine and naloxone therapy in the ambulatory environment.  Understand the key components and end points of delivering team based care to opiate dependent patients. Learning Objectives

Why Suboxone? (Buprenorphine/Naloxone)

Why Family Physicians?

 Schedules with physician to get off the opiates and not to increase them  Generally has more insight into their need for compliance  Willing to budget for physician visits and medication  Opens discussion about heroin relapse and “using”  Meds are rarely stolen  Rapidly get better Heroin Addict vs Chronic Pain Patient

 Tachycardia  Diarrhea  Diaphoresis  Tremulous  “Ancy”  Yawns Withdrawal Symptoms

 Suboxone™ Films (2mg,4mg, 8mg) – Buprenorphine/Naloxone  Subutex™ Tablets (2mg) – Buprenorphine

Mechanism of Action

 Family Physicians with a DEA license are eligible to apply for a waiver to prescribe Suboxone and Subutex.  The DEA grants the waiver by issuing a new DEA license to the Family Physician (no extra charge) that includes a second number, known as a “XDEA”. THE PROCESS

THE PROCESS becoming waivered….

Online, 9 hours CME…

Online, 8 hours CME…

 1. Run PDMP reports – mostly initiation/historical  2. Offer in house urine drug testing – 10 or 12 cup panel that includes buprenorphine ($6 cost, CLIA waived test)  3. Co-Signed Drug Contract  4. Behavioral Health integration – same EHR works best  5. Pharmacy Technician – assists with initiation and prior authorizations  6. Scribes assist with documentation  Works great with Direct Primary Care and Medicaid Team Based/PCMH/Integrated Care

Introduction to Suboxone What Family Physicians Can Offer Friday April 15th, 2016 John L Bender, MD, MBA,FAAFP